Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

FDA approves 150 mg strength of Warner Chilcott's Doryx delayed-release tablets for acne

June 27, 2008

Peplin treats first patient in phase IIb PEP-005 trial in actinic keratosis

June 25, 2008

Welichem Biotech completes phase IIa WBI-1001 clinical trial in atopic dermatitis

June 23, 2008

Avontec reports results from a phase I study of AVT-02 UE for inflammatory skin diseases

June 23, 2008

Novel antipsoriatic agents imparted in recent University of Sunderland patent

June 23, 2008

FDA Advisory Committee recommends approval of ustekinumab

June 18, 2008

Novel agents for skin wrinkling reported by Lipotec

June 13, 2008

Clinuvel to commence phase II CUV-1647 trials in solar urticaria

June 13, 2008

Phase III PEP-005 trial under SPA agreement with FDA to begin in Q3 2008

June 11, 2008

Intercytex completes enrollment in phase III trial of Cyzact in venous leg ulcers

June 9, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...